Sign up Australia
Proactive Investors - Run By Investors For Investors

Actinogen Medical opens SPP after successful $15 million placement

Funding will go towards the company's lead drug candidate Xanamem™.
close up of connected cells in a brain
Alzheimer’s disease is the most common form of dementia

Actinogan Medical Ltd (ASX:ACW) will open a share purchase plan (SPP) to its shareholders at the same price as its recently completed $15 million share placement.

The recent placement included a $10.5 million cornerstone investment from leading US biotech investors Biotechnology Value Fund, L.P.

The SPP will be priced at 5 cents and be on a first-come, first-served basis capped at $2.0 million.

The offer opens today and will close 11 July 2018.


Advancing Alzheimer’s disease drug

Actinogen’s lead drug candidate Xanamem™ represents a novel approach to treating Alzheimer’s disease – a condition with a significant unmet medical need.

It blocks the production of stress hormone cortisol, which appears to contribute to cognitive impairment, amyloid plaques and neural death - hallmarks of Alzheimer’s disease.

Alzheimer’s growing rapidly

Alzheimer’s disease is the most common form of dementia and has a debilitating effect on patients and their loved ones.

Alzheimer’s is also growing rapidly and is now the second leading cause of death in Australia behind ischaemic heart disease.

The American Alzheimer’s Association estimates that the direct healthcare cost of the disease was $US250 billion in 2013, and by 2050, the cost of care for people with the disease is expected to be over $US1 trillion, outstripping the cost of treating all other diseases.

Proceeds to fund ongoing drug development

The proceeds from this SPP will support the ongoing development of Xanamem through the company’s development plan.

This plan includes, among others, a study exploring a higher dose of Xanamem in Alzheimer’s disease and studies conducted in alternative clinical indications.

Expansion of the development plan for Xanamem into these new indications will enhance the value of the company’s data set.

View full ACW profile View Profile

Actinogen Medical Ltd Timeline

December 30 2016

Related Articles

June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development
Callitas CEO James Thompson
July 21 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
immunotherapy graphic
September 13 2018
A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use